SCHEMBL15051695

SCHEMBL15051695

Cc1cnc(F)cc1-n1cc(CO)c(-c2ccccc2Cl)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.41
MEN1 O00255 8/20 0.39
KMT2A Q03164 8/20 0.39
KDM4E B2RXH2 6/20 0.39
RAB9A P51151 3/20 0.39
LMNA P02545 2/20 0.39
NPC1 O15118 2/20 0.38
ALDH1A1 P00352 7/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MAPT P10636 4/20 0.37
ALPL P05186 1/20 0.37
HPGD P15428 3/20 0.37
HSD17B10 Q99714 3/20 0.36
MAPK1 P28482 2/20 0.36
TSHR P16473 1/20 0.36
POLB P06746 1/20 0.36
USP2 O75604 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HTT P42858 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15051327 0.80 POLB (0.38) GAAMEN1KMT2AKDM4ERAB9A
SCHEMBL15050763 0.80 KCNN4 (0.34) KMT2AMAPTTSHRPOLB
SCHEMBL15051538 0.80 ABL1 (0.49) RAB9ANPC1SMN1; SMN2
SCHEMBL15051266 0.79 MAPT (0.42) GAAMEN1KMT2AKDM4ERAB9A
SCHEMBL15051044 0.78 MC4R (0.35) GAAMEN1KMT2AKDM4ERAB9A
SCHEMBL15051324 0.73 DGAT1 (0.32) GAA
SCHEMBL15051645 0.67 PIK3C3 (0.39) SMN1; SMN2TDP1
SCHEMBL15051545 0.67 MAPT (0.43) KDM4ERAB9ANPC1ALDH1A1L3MBTL1
SCHEMBL15051607 0.67 KCNN4 (0.34) GAAKMT2ALMNAALDH1A1HPGD
SCHEMBL15051599 0.66 DHODH (0.43) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2793880-A1 HETEROARYLS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2014-10-29 EP disclosed
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165464-A1 HETEROARYLS AND USES THEREOF PIK3C2B, PI4KB, PIK3R4 GAA 217/4885MEN1 3929/4885KMT2A 2493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.